A 74-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and A 62-Year-Old Man with High-Risk Localized Prostate Cancer
Aaron Berger, MD, discusses how different formulations of abiraterone acetate can be selected based on patient compliance factors, particularly regarding fasting requirements, for treating both metastatic castration-resistant prostate cancer and high-risk localized prostate cancer cases.
EP. 1: A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
June 16th 2025A panelist discusses how a man aged 74 years with mCRPC who progressed on enzalutamide was successfully treated with abiraterone, highlighting the importance of selecting the appropriate formulation based on patient adherence and lifestyle factors.
EP. 2: Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
June 16th 2025A panelist discusses how adherence considerations are crucial when selecting between different abiraterone formulations, emphasizing that the microformulation offers flexibility by allowing administration with or without food compared with the traditional fasting requirements.
EP. 3: Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability
June 23rd 2025A panelist discusses how food significantly affects abiraterone absorption, particularly fatty meals, which can increase absorption to dangerous levels, making the microformulation advantageous by eliminating fasting concerns.
EP. 4: The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
June 23rd 2025A panelist discusses how patient comorbidities like diabetes and liver disease influence abiraterone formulation selection, noting that some physicians worry about steroid effects on blood glucose and the importance of monitoring liver function.
